Galmed Pharma (GLMD) Misses Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Galmed Pharma (GLMD) Misses Q1 EPS by 3c

Galmed Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update

May 16, 2016 8:03 AM EDT

TEL AVIV, Israel, May 16, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today reported financial results for the three months ended March 31, 2016.  The Company will host a conference call and webcast today to discuss the financial results and to provide an update on current developments with respect to its clinical programs for Aramchol.

Financial Summary First Quarter 2016 vs. First Quarter 2015:

Net loss of... More